Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- The United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) has granted authorization to Merck & Co Inc (NYSE:MRK) and Ridgeback Biotherapeutics' molnupiravir (MK-4482) for COVID-19.
- The approval marks the first oral antiviral medicine authorized to treat mild-to-moderate COVID-19 in adults who have at least one risk factor for developing severe illness.
- In the U.K., Lagevrio is the planned trademark for molnupiravir.
- Molnupiravir application is under review in the U.S. and Europe.
- Merck is actively working to submit applications to other regulatory agencies around the world.
- Related: Merck, Ridgeback File For Emergency Use Nod For COVID-19 Antiviral.
- Price Action: MRK shares are up 2.19% at $90.62 during the premarket session on the last check Thursday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!